Bentley Pharmaceuticals Reports $0.12 Diluted EPS on Record Revenues of $24.8 Million in the Second Quarter.
Business Wire › August 03, 2005
Linked as:
Extract
Bentley Pharmaceuticals Reports $0.12 Diluted EPS on Record Revenues of $24.8 Million in the Second Quarter.
EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced financial results for the second quarter and six months ended June 30, 2005.
Total revenues grew 34% (29% in constant currency) to a record $24.8 million in the second quarter of 2005 compared to the same three month period of the prior year. Net product sales grew 35% (29% in constant currency) and licensing and collaboration revenues increased to approximately $1.3 million in the second quarter. Royalty revenues from sales of Testim by the Company's licensee, Auxilium Pharmaceuticals, Inc., increased 94% for the three month period when compared to the second quarter of 2004. In addition to the growth in Testim royalty revenues, the following contributed to the Company's s...See the full content of this document
Sponsored links
